CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 8. Treatment with PKC{delta} antisense-abrogated PKC{delta}-mediated radiosensitivity. A, protein extracts (60 µg) of growing vector control and PKC{delta}-overexpressed NIH3T3 cells with or without PKC{delta} antisense (ISIS 11514, 11515), sense oligonucleotides (ISIS 22083, ISIS 22086), or rottlerin (5 µM) were prepared, separated by SDS-PAGE, and analyzed by Western blotting. B, control vector and PKC{delta}-overexpressing NIH3T3 cells with or without PKC{delta} antisense (ISIS 11514, 11515), sense oligonucleotides (ISIS 22083, ISIS 22086), or rottlerin (5 µM) were harvested after incubation for the periods indicated after 5 Gy radiation, and cell cycle distribution was analyzed after by a flow cytometer staining with propidium iodide. C, surviving fraction of vector control and PKC{delta}-overexpressing NIH3T3 cells with or without PKC{delta} antisense (ISIS 11514, 11515), sense oligonucleotides (ISIS 22083, ISIS 22086), or rottlerin (5 µM) was obtained by colony-forming assay after irradiation. D, DNA fragmentation measured by Hoechst 33258 staining 48 h after 5-Gy radiation as described under "Materials and Methods." Error bar, mean ± SD from three independent experiments.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation